{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T08:42:55Z","timestamp":1734338575454,"version":"3.30.2"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.esmogo.2024.100110","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T19:54:54Z","timestamp":1732132494000},"page":"100110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study"],"prefix":"10.1016","volume":"6","author":[{"given":"A.","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Felismino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Donadio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Catani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.M.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Weschenfelder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.D.","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.P.","family":"Riechelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmogo.2024.100110_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients","volume":"25","author":"Schmoll","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmogo.2024.100110_bib2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.esmogo.2024.100110_bib3","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","article-title":"Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group","volume":"25","author":"Porschen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"year":"2017","series-title":"Common Terminology Criteria for Adverse Events","key":"10.1016\/j.esmogo.2024.100110_bib4"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100110_bib5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.molmed.2011.07.002","article-title":"Balancing acts: the role of TGF-\u03b2 in the mucosal immune system","volume":"17","author":"Konkel","year":"2011","journal-title":"Trends Mol Med"},{"issue":"19-20","key":"10.1016\/j.esmogo.2024.100110_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00508-019-01539-2","article-title":"Association of sprue-like enteropathy and angiotensin receptor-1 antagonists","volume":"131","author":"Wenzel","year":"2019","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100110_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/gut.49.2.190","article-title":"Loss of transforming growth factor \u03b2 signalling in the intestine contributes to tissue injury in inflammatory bowel disease","volume":"49","author":"Hahm","year":"2001","journal-title":"Gut"},{"issue":"11-12","key":"10.1016\/j.esmogo.2024.100110_bib8","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/apt.13413","article-title":"Immunopathogenesis of olmesartan-associated enteropathy","volume":"42","author":"Marietta","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.esmogo.2024.100110_bib9","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100110_bib10","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.mayocp.2012.10.005","article-title":"Olmesartan and intestinal adverse effects in the ROADMAP study","volume":"87","author":"Menne","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100110_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/gastro\/goz019","article-title":"Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review","volume":"7","author":"Kamal","year":"2019","journal-title":"Gastroenterol Rep"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100110_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/10600280231191834","article-title":"Angiotensin receptor blocker\u2013related sprue-like enteropathy: review of food and drug administration adverse event reporting system","volume":"58","author":"Meader","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.esmogo.2024.100110_bib13","first-page":"1","article-title":"Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis","volume":"14","author":"Felismino","year":"2020","journal-title":"Ecancermedicalscience"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100110_bib14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.esmogo.2024.100110_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100110_bib16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/gutjnl-2019-318512","article-title":"Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?","volume":"69","author":"Garg","year":"2020","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.esmogo.2024.100110_bib22","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study","volume":"26","author":"Hochster","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100110_bib23","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.esmogo.2024.100110_bib18","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","volume":"25","author":"D\u00edaz-Rubio","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100110_bib25","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/annonc\/mdn370","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study","volume":"19","author":"Rothenberg","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100110_bib19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.25369","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer","volume":"128","author":"Ducreux","year":"2011","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100110_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00432-008-0454-7","article-title":"Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil\/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401","volume":"135","author":"Comella","year":"2009","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmogo.2024.100110_bib26","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S1470-2045(14)70486-3","volume":"15","author":"Schmoll","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100110_bib20","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/cncr.23013","article-title":"Severe enteropathy among patients with stage II\/III colon cancer treated on a randomized trial of bolus 5-fluorouracil\/leucovorin plus or minus oxaliplatin: a prospective analysis","volume":"110","author":"Kuebler","year":"2007","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100110_bib21","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/annonc\/mdw404","article-title":"Phase III trial comparing 3-6 months of adjuvant FOLFOX4\/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial","volume":"27","author":"Lonardi","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100110_bib27","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100110_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100110_bib29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00520-014-2461-3","article-title":"Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study","volume":"23","author":"Chen","year":"2015","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100110_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/fcp.12741","article-title":"Diarrhea and angiotensin II receptor blockers: is there any difference between the different drugs?","volume":"36","author":"Guion-Firmin","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100110_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/fcp.12741","article-title":"Diarrhea and angiotensin II receptor blockers: is there any difference between the different drugs?","volume":"36","author":"Guion-Firmin","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100110_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/apt.14518","article-title":"Use of olmesartan and enteropathy outcomes: a multi-database study","volume":"47","author":"Dong","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100110_bib33","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/gutjnl-2015-309690","article-title":"Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study","volume":"65","author":"Basson","year":"2015","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100110_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pds.4402","article-title":"Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy","volume":"27","author":"Malfertheiner","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100110_bib35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bbrc.2012.07.003","article-title":"Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA-6 and the Bax pathway","volume":"424","author":"Sun","year":"2012","journal-title":"Biochem Biophys Res Commun"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:37:05Z","timestamp":1734334625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"alternative-id":["S2949819824000712"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100110","relation":{},"ISSN":["2949-8198"],"issn-type":[{"type":"print","value":"2949-8198"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factor of severe diarrhea and enterocolitis induced by CAPOX: a retrospective multicenter study","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100110"}}